- Home
- SNOA vs APM Comparison
SNOA vs APM Comparison
Compare SNOA & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNOA
- APM
- Stock Information
- Founded
- SNOA 1999
- APM 2010
- Country
- SNOA United States
- APM United Kingdom
- Employees
- SNOA N/A
- APM N/A
- Industry
- SNOA Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SNOA Health Care
- APM Health Care
- Exchange
- SNOA Nasdaq
- APM Nasdaq
- Market Cap
- SNOA 6.4M
- APM 6.9M
- IPO Year
- SNOA 2007
- APM 2018
- Fundamental
- Price
- SNOA $3.06
- APM $1.41
- Analyst Decision
- SNOA
- APM
- Analyst Count
- SNOA 0
- APM 0
- Target Price
- SNOA N/A
- APM N/A
- AVG Volume (30 Days)
- SNOA 52.3K
- APM 10.2M
- Earning Date
- SNOA 08-07-2025
- APM 08-19-2025
- Dividend Yield
- SNOA N/A
- APM N/A
- EPS Growth
- SNOA N/A
- APM N/A
- EPS
- SNOA N/A
- APM N/A
- Revenue
- SNOA $14,912,000.00
- APM N/A
- Revenue This Year
- SNOA $23.00
- APM N/A
- Revenue Next Year
- SNOA $24.59
- APM N/A
- P/E Ratio
- SNOA N/A
- APM N/A
- Revenue Growth
- SNOA 17.43
- APM N/A
- 52 Week Low
- SNOA $1.75
- APM $0.46
- 52 Week High
- SNOA $5.93
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- SNOA 41.95
- APM 50.48
- Support Level
- SNOA $2.91
- APM $1.21
- Resistance Level
- SNOA $3.16
- APM $1.44
- Average True Range (ATR)
- SNOA 0.20
- APM 0.12
- MACD
- SNOA -0.03
- APM -0.04
- Stochastic Oscillator
- SNOA 24.43
- APM 30.28
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.